Literature DB >> 15906358

Efficient induction of T-cell responses to carcinoembryonic antigen by a heterologous prime-boost regimen using DNA and adenovirus vectors carrying a codon usage optimized cDNA.

Carmela Mennuni1, Francesco Calvaruso, Andrea Facciabene, Luigi Aurisicchio, Mariangela Storto, Elisa Scarselli, Gennaro Ciliberto, Nicola La Monica.   

Abstract

The immunogenic properties of plasmid DNA and recombinant adenovirus (Ad) encoding the carcinoembryonic antigen (CEA) were examined in mice by measuring both the amplitude and type of immune response, and the immunogenicity of codon usage optimized cDNA encoding CEA (CEAopt) was assessed both in C57Bl/6 and CEA transgenic mice. Vectors were injected into quadriceps muscle either alone or in combination, and plasmid DNA was electroporated to enhance gene expression efficiency and immunogenicity. Injection of plasmid pVIJ/CEA followed by Ad-CEA boost elicited the highest amplitude of both CD4+ and CD8+ T-cell response to the target antigen, measured by both IFNgamma-ELIspot assay and intracellular staining. Vectors carrying cDNA of CEAopt expressed a greater amount of the CEA protein than their wild-type counterparts, and this enhanced expression was associated with greater immunogenicity. Both CD4+ and CD8+ T-cell epitopes were mapped in the C-terminal portion of the protein. In CEA transgenic mice, only immunization based on repeated injections of pVIJ/CEAopt followed by Ad-CEAopt was able to elicit a CEA-specific CD8+ T-cell response, whereas the wild-type vectors did not break tolerance to this target antigen. MC38-CEA tumor cells injected s.c. in CEA transgenic mice vaccinated with CEAopt vectors exhibited delayed growth kinetics. These studies demonstrate that this type of genetic vaccine is highly immunogenic and can break tolerance to CEA tumor antigen in CEA transgenic mice. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15906358     DOI: 10.1002/ijc.21188

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  22 in total

1.  MC32 tumor cells acquire Ag-specific CTL resistance through the loss of CEA in a colon cancer model.

Authors:  Sang-Yeul Lee; Jeong-Im Sin
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

2.  Vaccination with a recombinant Saccharomyces cerevisiae expressing a tumor antigen breaks immune tolerance and elicits therapeutic antitumor responses.

Authors:  Elizabeth K Wansley; Mala Chakraborty; Kenneth W Hance; Michael B Bernstein; Amanda L Boehm; Zhimin Guo; Deborah Quick; Alex Franzusoff; John W Greiner; Jeffrey Schlom; James W Hodge
Journal:  Clin Cancer Res       Date:  2008-07-01       Impact factor: 12.531

Review 3.  DNA vaccines for prostate cancer.

Authors:  Christopher D Zahm; Viswa Teja Colluru; Douglas G McNeel
Journal:  Pharmacol Ther       Date:  2017-02-07       Impact factor: 12.310

4.  Superior Immunologic and Therapeutic Efficacy of a Xenogeneic Genetic Cancer Vaccine Targeting Carcinoembryonic Human Antigen.

Authors:  Luigi Aurisicchio; Giuseppe Roscilli; Emanuele Marra; Laura Luberto; Rita Mancini; Nicola La Monica; Gennaro Ciliberto
Journal:  Hum Gene Ther       Date:  2015-06       Impact factor: 5.695

Review 5.  DNA vaccines, electroporation and their applications in cancer treatment.

Authors:  Si-Hyeong Lee; Sayyed Nilofar Danishmalik; Jeong-Im Sin
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

6.  Maraba virus as a potent oncolytic vaccine vector.

Authors:  Jonathan G Pol; Liang Zhang; Byram W Bridle; Kyle B Stephenson; Julien Rességuier; Stephen Hanson; Lan Chen; Natasha Kazdhan; Jonathan L Bramson; David F Stojdl; Yonghong Wan; Brian D Lichty
Journal:  Mol Ther       Date:  2013-10-25       Impact factor: 11.454

7.  Coadministration of telomerase genetic vaccine and a novel TLR9 agonist in nonhuman primates.

Authors:  Sridhar Dharmapuri; Daniela Peruzzi; Carmela Mennuni; Francesco Calvaruso; Saverio Giampaoli; Gaetano Barbato; Ekambar R Kandimalla; Sudhir Agrawal; Elisa Scarselli; Giuseppe Mesiti; Gennaro Ciliberto; Nicola La Monica; Luigi Aurisicchio
Journal:  Mol Ther       Date:  2009-07-21       Impact factor: 11.454

8.  Immunogenicity and therapeutic efficacy of a dual-component genetic cancer vaccine cotargeting carcinoembryonic antigen and HER2/neu in preclinical models.

Authors:  Luigi Aurisicchio; Daniela Peruzzi; Gloria Koo; Wei-Zen Wei; Nicola La Monica; Gennaro Ciliberto
Journal:  Hum Gene Ther       Date:  2013-12-21       Impact factor: 5.695

9.  Pharmacokinetic tuning of protein-antigen fusions enhances the immunogenicity of T-cell vaccines.

Authors:  Naveen K Mehta; Roma V Pradhan; Ava P Soleimany; Kelly D Moynihan; Adrienne M Rothschilds; Noor Momin; Kavya Rakhra; Jordi Mata-Fink; Sangeeta N Bhatia; K Dane Wittrup; Darrell J Irvine
Journal:  Nat Biomed Eng       Date:  2020-06-01       Impact factor: 25.671

10.  Enhancing Th2 immune responses against amyloid protein by a DNA prime-adenovirus boost regimen for Alzheimer's disease.

Authors:  Hong-Duck Kim; Jing-Ji Jin; J Adam Maxwell; Ken-ichiro Fukuchi
Journal:  Immunol Lett       Date:  2007-07-23       Impact factor: 3.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.